SciBase gains US private insurance reimbursement for its Nevisense platform, marking a pivotal step in the company's strategy to scale its AI-driven dermatological diagnostic technology across the American market.
SciBase has achieved a critical commercial milestone by securing its first private US insurance reimbursement policy for its Nevisense technology. This development removes a significant barrier to entry in the US market, enabling the company to transition from niche clinical usage to broader, subsidized adoption. The policy is supported by NCCN clinical guidelines, which validates the technology's role in detecting primary melanoma and supports the company's long-term goal of capturing a share of a $1 billion addressable market.
It allows for the reimbursement of Nevisense procedures, which facilitates broader clinical adoption and removes a major hurdle for commercial scaling in the US.
SciBase aims to capture a significant share of a $1 billion market with a target gross margin of 75%.
SciBase Holding AB has achieved a critical commercial milestone by securing its first medical policy from a private US insurer for its Nevisense skin assessment technology. This reimbursement approval validates the company's non-invasive AI-based diagnostic tool and removes a significant barrier to scaling operations in the US market. The company aims to capture a share of the $1 billion global skin assessment market while targeting a 75% gross margin.
It marks the first time a private US insurer has agreed to cover the Nevisense procedure, which is essential for transitioning from niche clinical use to widespread, subsidized adoption.
Nevisense uses AI and Electrical Impedance Spectroscopy (EIS) to provide objective, non-invasive assessments for early skin cancer detection and skin barrier evaluation.